Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Liraglutide and Peripheral Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 50
- Registration Number
- NCT04881110
- Locations
- 🇮🇹
Unit of Endocrinology and Metabolic Diseases and Unit of Diabetes, University of Campania Luigi Vanvitelli, Napoli, Italy
The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Xiangya Hospital of Central South University
- Registration Number
- NCT04839237
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin
- Conditions
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Corporacion Parc Tauli
- Target Recruit Count
- 116
- Registration Number
- NCT04829903
- Locations
- 🇵🇰
Zainab Khan, Lahore, Punjab, Pakistan
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT04775082
- Locations
- 🇺🇸
University of Minnesota_CPOM, Minneapolis, Minnesota, United States
🇺🇸UPMC Child Hosp-Pittsburgh, Pittsburgh, Pennsylvania, United States
🇲🇽Consultorio de Endocrinología y Pediatría, Puebla, Mexico
Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 57
- Registration Number
- NCT04657939
- Locations
- 🇬🇧
Leeds Teaching Hospitals Trust, Leeds, West Yorkshire, United Kingdom
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 414
- Registration Number
- NCT04605861
- Locations
- 🇨🇳
Zhongshan Hosital, Fudan University, Shanghai, China
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 80
- Registration Number
- NCT04575844
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Fondation Hôpital Saint-Joseph
- Target Recruit Count
- 18
- Registration Number
- NCT04529278
- Locations
- 🇫🇷
AURA Paris Site de Saint Ouen, Saint-Ouen, France
🇫🇷Hôpital Bichat, Paris, France
🇫🇷Groupe Hospitalier Paris Saint-Joseph, Paris, France
Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 300
- Registration Number
- NCT04525300
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 300
- Registration Number
- NCT04487743
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.